Q1 Earnings Forecast for BEAM Issued By Leerink Partnrs

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Beam Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings of ($1.26) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics' FY2026 earnings at ($5.09) EPS.

Other analysts have also issued reports about the company. Sanford C. Bernstein raised Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 7th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research note on Friday. Leerink Partners upgraded shares of Beam Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $27.00 to $39.00 in a research note on Wednesday, November 6th. Royal Bank of Canada upped their target price on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a "sector perform" rating in a research note on Wednesday. Finally, Guggenheim reaffirmed a "buy" rating and issued a $78.00 price objective on shares of Beam Therapeutics in a research report on Thursday. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $50.90.

Remove Ads

Beam Therapeutics Price Performance

Shares of NASDAQ:BEAM traded down $0.77 during midday trading on Thursday, hitting $26.34. 1,469,610 shares of the company's stock were exchanged, compared to its average volume of 1,297,222. The stock has a 50 day moving average price of $27.18 and a 200-day moving average price of $25.94. The company has a market cap of $2.20 billion, a PE ratio of -14.97 and a beta of 1.92. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $45.05.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, topping analysts' consensus estimates of ($1.25) by $0.16. The company had revenue of $30.00 million for the quarter, compared to analyst estimates of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. Beam Therapeutics's revenue for the quarter was down 90.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.73 earnings per share.

Insider Activity

In other news, CEO John M. Evans sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the transaction, the chief executive officer now directly owns 908,659 shares of the company's stock, valued at $24,306,628.25. This represents a 3.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christine Bellon sold 1,241 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the transaction, the insider now directly owns 102,968 shares of the company's stock, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. boosted its position in Beam Therapeutics by 59.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company's stock worth $87,044,000 after purchasing an additional 1,328,414 shares during the period. ARK Investment Management LLC boosted its holdings in Beam Therapeutics by 8.2% in the 4th quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company's stock worth $175,287,000 after buying an additional 536,930 shares during the period. Casdin Capital LLC boosted its holdings in Beam Therapeutics by 61.3% in the 4th quarter. Casdin Capital LLC now owns 1,250,000 shares of the company's stock worth $31,000,000 after buying an additional 475,000 shares during the period. State Street Corp boosted its holdings in shares of Beam Therapeutics by 12.5% in the third quarter. State Street Corp now owns 3,929,557 shares of the company's stock worth $96,274,000 after acquiring an additional 437,402 shares during the period. Finally, Nikko Asset Management Americas Inc. boosted its holdings in shares of Beam Therapeutics by 11.4% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,957,611 shares of the company's stock worth $98,109,000 after acquiring an additional 404,782 shares during the period. Institutional investors own 99.68% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.